Avidity Biosciences Inc Ordinary Shares RNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RNA is a good fit for your portfolio.
News
-
Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors
-
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
-
Avidity Biosciences to Participate in Upcoming Investor Conference
-
Avidity's Lead Program Gets FDA Breakthrough Designation
-
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Avidity Biosciences to Participate in Upcoming Investor Conferences
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $29.54
- Day Range
- $28.54–29.30
- 52-Week Range
- $4.84–30.52
- Bid/Ask
- $28.88 / $29.00
- Market Cap
- $2.77 Bil
- Volume/Avg
- 146,509 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 209.60
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 253
Comparables
Valuation
Metric
|
RNA
|
DYN
|
TRDA
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | 22.52 |
Price/Book Value | 3.40 | 5.13 | 1.77 |
Price/Sales | 209.60 | — | 2.93 |
Price/Cash Flow | — | — | 14.37 |
Price/Earnings
RNA
DYN
TRDA
Financial Strength
Metric
|
RNA
|
DYN
|
TRDA
|
---|---|---|---|
Quick Ratio | 12.34 | 2.41 | 2.33 |
Current Ratio | 12.47 | 2.53 | 2.38 |
Interest Coverage | — | — | — |
Quick Ratio
RNA
DYN
TRDA
Profitability
Metric
|
RNA
|
DYN
|
TRDA
|
---|---|---|---|
Return on Assets (Normalized) | −28.01% | −77.53% | 7.11% |
Return on Equity (Normalized) | −31.89% | −94.92% | 14.48% |
Return on Invested Capital (Normalized) | −35.83% | −88.19% | 7.18% |
Return on Assets
RNA
DYN
TRDA
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bpjchsrgp | Pzlm | $586.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bmrctpqj | Xvxdwj | $110.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vsdrthn | Lxptckj | $107.8 Bil | |
MRNA
| Moderna Inc | Tpstttvl | Cthws | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Ckqnqlv | Dkjq | $22.2 Bil | |
ARGX
| argenx SE ADR | Grhzbqjpp | Vptzq | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Yznbhjw | Zzscw | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jsvvmkmy | Npbpg | $15.1 Bil | |
INCY
| Incyte Corp | Nkhmjlml | Kbgdnk | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hyvbvzyjx | Zprwfk | $12.7 Bil |